drugset
Drugs / IODINE I 131 APAMISTAMAB
last change Apr 2025 re-read 3 minutes ago

IODINE I 131 APAMISTAMAB

also known as Iomab-B · Apamistamab iodine i-131 · apamistamab-I131 · I 131 moab bc8 · I-131-BC8 · Iodine (131i) apamistamab · Iodo (131i) apamistamab

Monoclonal antibody

Developed for
acute myeloid leukemia · diffuse large B-cell lymphoma
Investigated by
Actinium Pharmaceuticals · University of Texas Southwestern Medical Center

Trials 2

today NCT06768905 · Ph 1/2 NCT02665065 · Ph 3
2017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT06768905 Apr 2025 → May 2029 expected diffuse large B-cell lymphoma University of Texas Southwestern Medical Center Recruiting No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT02665065 Jun 2016 → Jun 2022 overdue acute myeloid leukemia Actinium Pharmaceuticals Active not recruiting Met primary

Press releases naming this drug 51 releases

DateIssuerRelease
2024-06-10 Actinium Pharmaceuticals Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting actiniumpharma.com ↗
2024-05-14 Actinium Pharmaceuticals Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial actiniumpharma.com ↗
2024-05-13 Actinium Pharmaceuticals Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting actiniumpharma.com ↗
2024-04-18 Actinium Pharmaceuticals Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting actiniumpharma.com ↗
2024-04-01 Actinium Pharmaceuticals Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting actiniumpharma.com ↗
2024-02-26 Actinium Pharmaceuticals Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® actiniumpharma.com ↗
2024-02-23 Actinium Pharmaceuticals Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® actiniumpharma.com ↗
2023-12-11 Actinium Pharmaceuticals Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation actiniumpharma.com ↗
2023-12-11 Actinium Pharmaceuticals Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia actiniumpharma.com ↗
2023-12-08 Actinium Pharmaceuticals Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition actiniumpharma.com ↗
2023-11-02 Actinium Pharmaceuticals Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial actiniumpharma.com ↗
2023-06-26 Actinium Pharmaceuticals SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data actiniumpharma.com ↗

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as IODINE I 131 APAMISTAMAB ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗
Known as Apamistamab iodine i-131 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗
Known as apamistamab-I131 “Iomab-B [apamistamab-I131] is currently studied in the registration-type phase 3 SIERRA trial” PMID 35350938 ↗ Mar 2022
Known as I 131 moab bc8 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗
Known as I-131-BC8 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗
Known as Iodine (131i) apamistamab ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗
Known as Iodo (131i) apamistamab ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗
Known as Iomab-B ClinicalTrials.gov intervention name — accepted as the source's own label NCT02665065 ↗
1

NCT06768905 ↗
Modality Monoclonal antibody — CHEMBL4297997 ↗